Physician profile
Sumesh Chandra
NPI 1477547602
$6,671.13
in general payments reported to CMS, 2019-2025
27 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $896 · 2021: $1,122 · 2022: $865 · 2023: $531 · 2024: $856 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,397.25 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $768.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $723.07 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $546.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.94 | 2019-2021 | |
| Radius Health, INC. | $355.19 | 2019-2020 | |
| Dexcom, INC. | $304.59 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $267.88 | 2020-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $265.28 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $220.65 | 2019-2024 | Omnipod |
| Abbvie INC. | $219.59 | 2021-2025 | Synthroid |
| Janssen Pharmaceuticals, INC | $188.36 | 2019 | |
| Corcept Therapeutics | $144.49 | 2024-2025 | Korlym |
| Kyowa Kirin, INC. | $144.42 | 2024 | Crysvita |
| Amryt Pharma Holdings LTD | $124.98 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $100.79 | 2021-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $84.63 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $63.84 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $63.26 | 2019-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $56.74 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $39.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $37.13 | 2019 | |
| Ibsa Pharma INC. | $34.61 | 2024-2025 | Tirosint, Flector, Licart |
| Medtronic Minimed, INC. | $34.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.11 | 2023-2025 | Jardiance, Tradjenta |
| Neurocrine Biosciences, INC. | $30.17 | 2025 | |
| Antares Pharma, INC. | $16.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumesh Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.